Welcome to the 2022 Targeted Therapies Forum’s breakout session, where renowned oncologist Dr. Dagogo-Jack delves into the nuances of BRAF and NTRK inhibitors and their pivotal role in early-stage NSCLC. Navigate the intricate pathways of these targeted treatments and understand their transformative potential in revolutionizing the landscape of non-small cell lung cancer (NSCLC) care.
Heartfelt appreciation to our dedicated sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech.
To stay updated on cutting-edge advancements in oncology, please visit http://cancerGRACE.org/. Engage, discuss, and share your insights with a community of experts at https://cancergrace.org/forum.